vTv Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference

HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO, and Aaron Burstein, SVP, Clinical Development, will be presenting a corporate overview at the Ladenburg Thalmann 2015 Healthcare Conference. The presentation will take place at 2:30 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City.

A live webcast of the presentation can be accessed on the News & Events section of the website. The webcast will be archived for 30 days following the presentation on the company website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150923005380/en/

vTv Therapeutics Inc.
Investors
The Trout Group
Marc Panoff, 646-378-2958
[email protected]
or
Media
BMC Communications
Brad Miles, 646-513-3125
[email protected]

Source: vTv Therapeutics Inc.

You May Also Be Interested In

• vTv Therapeutics to Participate in September Investor Conferences
• Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc.
• Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR